Analysts expect Smart Sand, Inc. (NASDAQ:SND) to report $0.16 EPS on March, 15.They anticipate $0.26 EPS change or 61.90% from last quarter’s $0.42 EPS. SND’s profit would be $6.46 million giving it 13.39 P/E if the $0.16 EPS is correct. After having $0.17 EPS previously, Smart Sand, Inc.’s analysts see -5.88% EPS growth. The stock increased 4.00% or $0.33 during the last trading session, reaching $8.57. About 382,173 shares traded. Smart Sand, Inc. (NASDAQ:SND) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
THROMBOOGENICS NV (OTCMKTS:TBGNF) had a decrease of 23.94% in short interest. TBGNF’s SI was 48,300 shares in February as released by FINRA. Its down 23.94% from 63,500 shares previously. It closed at $5.025 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
Among 6 analysts covering Smart Sand (NASDAQ:SND), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Smart Sand had 7 analyst reports since November 29, 2016 according to SRatingsIntel. The stock of Smart Sand, Inc. (NASDAQ:SND) earned “Buy” rating by Jefferies on Tuesday, December 13. The firm earned “Buy” rating on Tuesday, November 29 by Goldman Sachs. The firm has “Accumulate” rating by Johnson Rice given on Monday, January 9. Piper Jaffray initiated it with “Overweight” rating and $13.25 target in Tuesday, November 29 report. The rating was initiated by Tudor Pickering on Wednesday, December 7 with “Buy”. The stock has “Neutral” rating by Goldman Sachs on Friday, January 20. The firm earned “Outperform” rating on Tuesday, November 29 by Credit Suisse.
Smart Sand, Inc. engages in the excavation, processing, and sale of industrial sands for use in hydraulic fracturing activities in the gas and oil industry in the United States. The company has market cap of $346.17 million. The firm sells its products primarily to oil and natural gas exploration and production companies, and oilfield service companies. It has a 14.33 P/E ratio. As of December 31, 2016, it had approximately 332 million tons of proven recoverable sand reserves.
ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company has market cap of $185.08 million. The companyÂ’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It currently has negative earnings. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA.